FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564912185> ?p ?o ?g. }

• W2564912185 endingPage "49" @default.
• W2564912185 startingPage "37" @default.
• W2564912185 abstract "Biological therapies represent a fundamental innovation for the management of inflammatory bowel diseases (IBD). However, many biological originators have reached, or are about to reach, patent expiry and long-term therapy costs have become progressively unsustainable. CT-P13, a biosimilar of the anti-tumor necrosis factor (anti-TNF) monoclonal antibody infliximab, might represent a significant alternative to its originator, with the potential to decrease medical care costs and, therefore, become available to a large number of patients. In this systematic review, we analyzed the data from available clinical trials that recently investigated the validity of indication extrapolation of CT-P13 for the treatment of IBD in naïve patients and in patients who switched from its originator infliximab, focusing on clinical efficacy, safety and immunogenicity. A detailed literature search was developed a priori to identify articles that investigated the validity of indication extrapolation of CT-P13 for the treatment of IBD in TNF inhibitor treatment-naïve patients and in patients who switched from the originator infliximab. This was applied to Ovid MEDLINE, In-Process and Other Non-Indexed Citations, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus for content from 2012 to September 2016. We based our review on the available data from 11 studies that included a total of 1007 IBD patients: 570 patients suffering from Crohn’s disease (294 switched and 276 naïve), 435 patients suffering from ulcerative colitis (127 switched and 308 naïve), and two IBD unclassified patients (switched). Overall, no significant difference in efficacy and safety between the originator infliximab and its biosimilar CT-P13 was observed. When assessing the safety of CT-P13, we found that 9.2% of patients experienced adverse effects (4.1% infusion-related reactions and 4.3% infections). The analyzed studies did not report a significant difference in terms of efficacy, safety and immunogenicity when comparing the clinical experience with CT-P13 with the available literature data on the originator treatment in IBD. However, some debate is ongoing regarding interchangeability and immunogenicity." @default.
• W2564912185 created "2017-01-06" @default.
• W2564912185 creator A5012705049 @default.
• W2564912185 creator A5015749384 @default.
• W2564912185 creator A5017039749 @default.
• W2564912185 creator A5054660181 @default.
• W2564912185 date "2016-12-29" @default.
• W2564912185 modified "2023-10-09" @default.
• W2564912185 title "Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review" @default.
• W2564912185 cites W1477056058 @default.
• W2564912185 cites W1530709545 @default.
• W2564912185 cites W1594887498 @default.
• W2564912185 cites W1827882046 @default.
• W2564912185 cites W1967570746 @default.
• W2564912185 cites W1980464290 @default.
• W2564912185 cites W1997999969 @default.
• W2564912185 cites W2004039287 @default.
• W2564912185 cites W2004057177 @default.
• W2564912185 cites W2022888597 @default.
• W2564912185 cites W2024155192 @default.
• W2564912185 cites W2026116536 @default.
• W2564912185 cites W2029520632 @default.
• W2564912185 cites W2049580289 @default.
• W2564912185 cites W2054710465 @default.
• W2564912185 cites W2062523779 @default.
• W2564912185 cites W2071427170 @default.
• W2564912185 cites W2079732985 @default.
• W2564912185 cites W2105792933 @default.
• W2564912185 cites W2108332624 @default.
• W2564912185 cites W2121050884 @default.
• W2564912185 cites W2127693350 @default.
• W2564912185 cites W2130173462 @default.
• W2564912185 cites W2144472014 @default.
• W2564912185 cites W2162768160 @default.
• W2564912185 cites W2171297959 @default.
• W2564912185 cites W2208243538 @default.
• W2564912185 cites W2279977120 @default.
• W2564912185 cites W2293557195 @default.
• W2564912185 cites W2308369648 @default.
• W2564912185 cites W2321453230 @default.
• W2564912185 cites W2342216265 @default.
• W2564912185 cites W2342464058 @default.
• W2564912185 cites W2345220764 @default.
• W2564912185 cites W2521883132 @default.
• W2564912185 cites W2531216194 @default.
• W2564912185 cites W2615184173 @default.
• W2564912185 cites W3149527659 @default.
• W2564912185 doi "https://doi.org/10.1007/s40259-016-0206-1" @default.
• W2564912185 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28035633" @default.
• W2564912185 hasPublicationYear "2016" @default.
• W2564912185 type Work @default.
• W2564912185 sameAs 2564912185 @default.
• W2564912185 citedByCount "30" @default.
• W2564912185 countsByYear W25649121852017 @default.
• W2564912185 countsByYear W25649121852018 @default.
• W2564912185 countsByYear W25649121852019 @default.
• W2564912185 countsByYear W25649121852020 @default.
• W2564912185 countsByYear W25649121852021 @default.
• W2564912185 countsByYear W25649121852022 @default.
• W2564912185 crossrefType "journal-article" @default.
• W2564912185 hasAuthorship W2564912185A5012705049 @default.
• W2564912185 hasAuthorship W2564912185A5015749384 @default.
• W2564912185 hasAuthorship W2564912185A5017039749 @default.
• W2564912185 hasAuthorship W2564912185A5054660181 @default.
• W2564912185 hasBestOaLocation W25649121852 @default.
• W2564912185 hasConcept C126322002 @default.
• W2564912185 hasConcept C168563851 @default.
• W2564912185 hasConcept C17744445 @default.
• W2564912185 hasConcept C177713679 @default.
• W2564912185 hasConcept C189708586 @default.
• W2564912185 hasConcept C199539241 @default.
• W2564912185 hasConcept C2776478404 @default.
• W2564912185 hasConcept C2777138892 @default.
• W2564912185 hasConcept C2778260677 @default.
• W2564912185 hasConcept C2778715236 @default.
• W2564912185 hasConcept C2779134260 @default.
• W2564912185 hasConcept C2779280984 @default.
• W2564912185 hasConcept C2779473830 @default.
• W2564912185 hasConcept C2780479503 @default.
• W2564912185 hasConcept C535046627 @default.
• W2564912185 hasConcept C59491497 @default.
• W2564912185 hasConcept C71924100 @default.
• W2564912185 hasConceptScore W2564912185C126322002 @default.
• W2564912185 hasConceptScore W2564912185C168563851 @default.
• W2564912185 hasConceptScore W2564912185C17744445 @default.
• W2564912185 hasConceptScore W2564912185C177713679 @default.
• W2564912185 hasConceptScore W2564912185C189708586 @default.
• W2564912185 hasConceptScore W2564912185C199539241 @default.
• W2564912185 hasConceptScore W2564912185C2776478404 @default.
• W2564912185 hasConceptScore W2564912185C2777138892 @default.
• W2564912185 hasConceptScore W2564912185C2778260677 @default.
• W2564912185 hasConceptScore W2564912185C2778715236 @default.
• W2564912185 hasConceptScore W2564912185C2779134260 @default.
• W2564912185 hasConceptScore W2564912185C2779280984 @default.
• W2564912185 hasConceptScore W2564912185C2779473830 @default.
• W2564912185 hasConceptScore W2564912185C2780479503 @default.
• W2564912185 hasConceptScore W2564912185C535046627 @default.
• W2564912185 hasConceptScore W2564912185C59491497 @default.

• next